Welcome Wondros Family and
Friends! We are beta testing and need
your help improving this product.
Share Feedback
Locations
44 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
Extension period through Week 108
Accepts healthy volunteers
No
Age
12 Years +
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Completed
Study Type
Interventional
Timeframe
Through study completion, an average 1 year
Accepts healthy volunteers
No
Age
4 Years - 18 Years
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Recruiting
Study Type
Interventional
Timeframe
2 weeks
Accepts healthy volunteers
No
Age
18 Years - 75 Years
Gender
All
Placebo Arm
No
Locations
38 locations
Status
Recruiting
Study Type
Interventional
Timeframe
at every single visit up to 60 months
Accepts healthy volunteers
No
Age
18 Years - 70 Years
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
Change from Baseline to End of Study (week 12)
Accepts healthy volunteers
No
Age
18 Years - 85 Years
Gender
All
Placebo Arm
Yes
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and ma...
Sponsored by:
Incyte Corporation
Trial Location:
Northwestern University, Chicago, Illinois 60611, United States
Estimated trial timing:
September 24, 2020 - November 04, 2022
To determine the effectiveness of the use of probiotics in patients with a diagnosis of complicated appendicitis on antibiotic associated diarrhea ...
Sponsored by:
Children's Health
Trial Location:
Children's Health Children's Medical Center, Dallas, Texas 75235, United States
Estimated trial timing:
September 08, 2020 - February 28, 2022
The purpose of this study is to examine if sending mild electrical signals just under your skin will improve atrial fibrillation symptoms by contro...
Sponsored by:
Cedars-Sinai Medical Center
Trial Location:
CedarsSinaiMC, Los Angeles, California 90048, United States
Estimated trial timing:
November 24, 2021 - July 01, 2023
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, dox...
Sponsored by:
Acerta Pharma BV
Trial Location:
Research Site, Clayton, 3168, Australia
Estimated trial timing:
October 08, 2020 - August 31, 2026
Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
Sponsored by:
Metagenics, Inc.
Trial Location:
Hypertension Institute, Nashville, Tennessee 37205, United States
Estimated trial timing:
August 18, 2020 - December 30, 2022
Our website uses cookies, as almost all websites do, to help provide you with the best experience we can. You can learn more about all the cookies and the information we collect by reading our Privacy Policy.